|
EP2379598B1
(en)
*
|
2009-01-19 |
2015-03-11 |
Innate Pharma |
Anti-kir3d antibodies
|
|
RU2682449C2
(ru)
|
2012-09-19 |
2019-03-19 |
Иннейт Фарма |
Связывающие kir3dl2 агенты
|
|
DK3896088T3
(da)
|
2013-02-20 |
2025-09-29 |
Innate Pharma |
Behandling af perifert t-cellelymfom
|
|
EP3116908B1
(en)
|
2014-03-14 |
2019-06-26 |
Innate Pharma |
Humanized kir3dl2 antibodies
|
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
|
JP6822849B2
(ja)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的ＮＫｐ４６結合タンパク質
|
|
WO2016030488A1
(en)
*
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
|
US10487153B2
(en)
|
2015-06-10 |
2019-11-26 |
National Research Council Of Canada |
Carbonic anhydrase IX-specific antibodies and uses thereof
|
|
JP6840682B2
(ja)
|
2015-06-23 |
2021-03-10 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的抗原結合タンパク質
|
|
AU2016284871B2
(en)
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific NK engager proteins
|
|
WO2017156423A2
(en)
*
|
2016-03-11 |
2017-09-14 |
Integrated Biotherapeutics, Inc. |
Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
|
|
US10858431B2
(en)
*
|
2016-06-30 |
2020-12-08 |
Trellis Bioscience, Llc |
Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
|
|
WO2018073363A1
(en)
|
2016-10-21 |
2018-04-26 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
|
EP3559032A1
(en)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
WO2018148223A1
(en)
*
|
2017-02-09 |
2018-08-16 |
Memorial Sloan Kettering Cancer Center |
Anti-kir3dl1 antibodies
|
|
US10781265B2
(en)
*
|
2017-05-24 |
2020-09-22 |
Development Center For Biotechnology |
Humanized antibodies against Globo H and uses thereof in cancer treatments
|
|
EP3638306A4
(en)
*
|
2017-06-15 |
2020-07-01 |
Development Center for Biotechnology |
ANTIBODY DRUG CONJUGATES CONTAINING ANTI-GLOBO H ANTIBODIES AND USES THEREOF
|
|
US20180371089A1
(en)
*
|
2017-06-22 |
2018-12-27 |
Development Center For Biotechnology |
Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
|
|
EP3713959A1
(en)
|
2017-11-21 |
2020-09-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
WO2019156223A1
(ja)
*
|
2018-02-09 |
2019-08-15 |
国立大学法人大阪大学 |
チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
|
|
WO2020035345A1
(en)
|
2018-08-14 |
2020-02-20 |
Innate Pharma |
Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
|
|
BR112021014236A2
(pt)
|
2019-01-22 |
2021-09-28 |
Innate Pharma |
Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia
|
|
EP4037712A4
(en)
|
2019-10-04 |
2023-11-01 |
Albert Einstein College of Medicine |
KIR3DL3 IS AN IMMUNE SYSTEM INHIBITANT RECEPTOR AND USES THEREOF
|
|
CN110950960B
(zh)
*
|
2019-11-26 |
2021-05-14 |
中国农业大学 |
基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法
|
|
AU2021244200A1
(en)
*
|
2020-03-23 |
2022-11-24 |
Bristol-Myers Squibb Company |
Anti-CCR8 antibodies for treating cancer
|
|
CN113817052A
(zh)
*
|
2020-06-19 |
2021-12-21 |
南京金斯瑞生物科技有限公司 |
抗SARS-CoV-2核衣壳蛋白单克隆抗体及其制备方法和用途
|
|
AU2022218137A1
(en)
|
2021-02-03 |
2023-08-24 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CN117321087A
(zh)
|
2021-03-26 |
2023-12-29 |
先天制药公司 |
包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
|
|
WO2022214432A1
(en)
|
2021-04-05 |
2022-10-13 |
Innate Pharma |
Immunohistochemistry methods and kir3dl2-specific reagents
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
CN117616050A
(zh)
|
2021-06-09 |
2024-02-27 |
先天制药公司 |
与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
KR20240019786A
(ko)
|
2021-06-09 |
2024-02-14 |
이나뜨 파르마 에스.에이. |
Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
|
|
CN113248609B
(zh)
*
|
2021-07-14 |
2021-09-10 |
深圳市盛波尔生命科学技术有限责任公司 |
针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
|
|
KR20240040098A
(ko)
*
|
2021-07-30 |
2024-03-27 |
알.피.쉐러 테크놀러지즈 엘엘씨 |
넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
EP4587122A1
(en)
|
2022-09-15 |
2025-07-23 |
Avidicure IP B.V. |
Multispecific antigen binding proteins for stimulating nk cells and use thereof
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
|
CN117801108B
(zh)
*
|
2023-12-06 |
2024-06-07 |
无锡傲锐东源生物科技有限公司 |
抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191139A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of her2-specific antigen binding proteins and cytokines
|
|
WO2025245386A1
(en)
*
|
2024-05-23 |
2025-11-27 |
La Jolla Institute For Immunology |
Kir3dl2 as an anti-cancer target
|
|
WO2026087748A1
(en)
|
2024-10-24 |
2026-04-30 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
|